Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.5 USD | -3.64% | -8.27% | +41.45% |
Financials (USD)
Sales 2024 * | 42.79M | Sales 2025 * | 114M | Capitalization | 1.79B |
---|---|---|---|---|---|
Net income 2024 * | -263M | Net income 2025 * | -345M | EV / Sales 2024 * | 40 x |
Net cash position 2024 * | 76.75M | Net cash position 2025 * | 15.43M | EV / Sales 2025 * | 15.5 x |
P/E ratio 2024 * |
-6.97
x | P/E ratio 2025 * |
-5.63
x | Employees | 385 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.65% |
Latest transcript on Agios Pharmaceuticals, Inc.
1 day | -3.64% | ||
1 week | -8.27% | ||
Current month | -3.08% | ||
1 month | -0.54% | ||
3 months | -4.52% | ||
6 months | +41.07% | ||
Current year | +41.45% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 55 | 22-08-07 |
Cecilia Jones
DFI | Director of Finance/CFO | 49 | 22-09-25 |
Jacqualyn Fouse
CHM | Chairman | 62 | 17-12-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Capello
BRD | Director/Board Member | 69 | 23-05-31 |
Director/Board Member | 64 | 14-12-08 | |
May Kin Ho
BRD | Director/Board Member | 71 | 15-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.52% | 1 M€ | -0.95% | - | |
0.16% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 31.5 | -3.64% | 605,230 |
24-05-23 | 32.69 | -2.24% | 540,115 |
24-05-22 | 33.44 | -1.30% | 656,166 |
24-05-21 | 33.88 | +2.08% | 812,599 |
24-05-20 | 33.19 | -3.35% | 469,075 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.45% | 1.79B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AGIO Stock